FDA Approved TONMYA for Fibromyalgia Treatment
The FDA approved a new non-opioid fibromyalgia medication in August 2025 to help patients manage chronic pain.
Updated on Oct. 7, 2026 in Substance Abuse
Live Poll
Do you feel new FDA-approved treatments are effectively improving options for chronic pain sufferers?
In August 2025, the FDA approved TONMYA as a new treatment option for adults living with fibromyalgia. This medication represents the first new therapy for the condition in over 15 years.
Why it matters
The approval provides a new non-opioid therapeutic option for millions of Americans suffering from fibromyalgia. It was granted based on evidence from clinical trials demonstrating significant pain reduction.
The FDA approved the therapy based on three Phase 3 clinical trials, with two studies demonstrating statistically significant pain reduction compared to placebo. Approximately 10 million U.S. adults are diagnosed with fibromyalgia.
The players
Food and Drug Administration
The federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
The details
TONMYA is a sublingual tablet containing cyclobenzaprine hydrochloride that is taken once daily at bedtime for rapid absorption. It offers a non-opioid approach to managing the symptoms experienced by patients with the chronic condition.
Timeline
The FDA officially approved TONMYA for use in August 2025.
Health Landscape
This approval marks the end of a 15-year period without new pharmacological advancements for fibromyalgia patients. It shifts the treatment landscape by introducing a novel non-opioid option into a market that has long relied on legacy medications.
Patients may now consult with their healthcare providers to determine if this once-daily sublingual tablet is an appropriate addition to their treatment regimen. The non-opioid nature of the drug provides an alternative for those seeking to avoid traditional pain management protocols.
The takeaway
This new therapy offers a significant milestone for those living with the daily challenges of fibromyalgia. Patients should discuss potential benefits and integration strategies with their primary care physicians.
Further reading
Learn more about advancements in pain management and Substance Abuse research on our portal.
More information
For comprehensive clinical details, visit the official medication information portal.
Source note: This article includes information reported by NBC Palm Springs.
Live Poll
Do you feel new FDA-approved treatments are effectively improving options for chronic pain sufferers?
